Neuronal Acetylcholine Receptor Subunit Beta 2 Therapeutics Pipeline Report 2016 - Review of 5 Companies & 11 Molecules - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016" report to their offering.

Neuronal Acetylcholine Receptor Subunit Beta 2 pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by Companies and remaining by the Universities/Institutes.

Neuronal Acetylcholine Receptor Subunit Beta 2 - Pipeline Review, H2 2016, outlays comprehensive information targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuronal acetylcholine receptor subunit beta-2 is a protein encoded by the CHRNB2 gene. Acetylcholine binds to this receptor. This results in extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions. The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 4 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

1. Introduction
2. Neuronal Acetylcholine Receptor Subunit Beta 2 Overview
3. Therapeutics Development
4. Pipeline Products for Neuronal Acetylcholine Receptor Subunit Beta 2 - Overview
5. Pipeline Products for Neuronal Acetylcholine Receptor Subunit Beta 2 - Comparative Analysis
6. Neuronal Acetylcholine Receptor Subunit Beta 2 - Therapeutics under Development by Companies
7. Neuronal Acetylcholine Receptor Subunit Beta 2 - Therapeutics under Investigation by Universities/Institutes
8. Neuronal Acetylcholine Receptor Subunit Beta 2 Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Neuronal Acetylcholine Receptor Subunit Beta 2 - Products under Development by Companies
13. Neuronal Acetylcholine Receptor Subunit Beta 2 - Products under Investigation by Universities/Institutes
14. Neuronal Acetylcholine Receptor Subunit Beta 2 - Companies Involved in Therapeutics Development

• Catalyst Biosciences, Inc.
• H. Lundbeck A/S
• NeuroDerm Ltd.
• Saniona AB
• Suven Life Sciences Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/kq2qhs/neuronal

Related Topics: Central Nervous System Drugs